Albiero Mattia, Fullin Alice, Villano Gianmarco, Biasiolo Alessandra, Quarta Santina, Bernardotto Simone, Turato Cristian, Ruvoletto Mariagrazia, Fadini Gian Paolo, Pontisso Patrizia, Morpurgo Margherita
Department of Medicine, The University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
Veneto Institute of Molecular Medicine, Via G. Orus 2, 35129 Padova, Italy.
Pharmaceutics. 2022 Sep 14;14(9):1944. doi: 10.3390/pharmaceutics14091944.
Foot ulcerations are a disabling complication of diabetes and no treatment is currently available based on disease mechanisms. The protein serpin B3 (SB3) was identified as a positive biomarker of successful diabetic wound healing; therefore, its exogenous administration may promote healing. The topical administration of SB3 is challenging due to its protein nature. Physical entrapment in wet sol-gel silica can stabilize the protein's conformation and permit its sustained delivery. However, irreversible syneresis and poor viscoelastic properties hamper wet sol-gel silica application as a semisolid vehicle. To overcome these limits, a sol-gel silica/hydroxypropylmethylcellulose (HPMC) hydrogel blend was developed. SB3 entrapped in 8% SiO wet sol-gel silica preserved its structure, was stabilized against denaturation, and was slowly released for at least three days. Blending a silica gel with an HPMC-glycerol (metolose-G) hydrogel permitted spreadability without affecting the protein's release kinetics. When administered in vivo, SB3 in silica/metolose-G-but not in solution or in metolose-G alone-accelerated wound healing in SB3 knockout and diabetic mouse models. The results confirmed that SB3 is a new pharmacological option for the treatment of chronic ulcers, especially when formulated in a slow-releasing vehicle. Silica-metolose-G represents a novel type of semisolid dosage form which could also be applied for the formulation of other bioactive proteins.
足部溃疡是糖尿病的一种致残性并发症,目前尚无基于疾病机制的治疗方法。蛋白丝氨酸蛋白酶抑制剂B3(SB3)被确定为糖尿病伤口成功愈合的阳性生物标志物;因此,外源性给予SB3可能促进愈合。由于其蛋白质性质,SB3的局部给药具有挑战性。物理包裹在湿溶胶-凝胶二氧化硅中可以稳定蛋白质的构象并使其持续释放。然而,不可逆的脱水收缩和较差的粘弹性阻碍了湿溶胶-凝胶二氧化硅作为半固体载体的应用。为了克服这些限制,开发了一种溶胶-凝胶二氧化硅/羟丙基甲基纤维素(HPMC)水凝胶混合物。包裹在8%SiO湿溶胶-凝胶二氧化硅中的SB3保持了其结构,对变性具有稳定性,并能缓慢释放至少三天。将硅胶与HPMC-甘油(甲基纤维素-G)水凝胶混合可实现铺展性,而不影响蛋白质的释放动力学。在体内给药时,二氧化硅/甲基纤维素-G中的SB3(而非单独的溶液或甲基纤维素-G中的SB3)在SB3基因敲除和糖尿病小鼠模型中加速了伤口愈合。结果证实,SB3是治疗慢性溃疡的一种新的药理学选择,特别是当制成缓释载体时。二氧化硅-甲基纤维素-G代表了一种新型的半固体剂型,也可用于其他生物活性蛋白的制剂。